MyMD Pharmaceuticals announces results from Supera-CBD study

MyMD Pharmaceuticals announced results from a preclinical study of its investigational cannabinoid Supera-CBD, a novel, synthetic, non-toxic cannabidiol, or CBD, analog. In the study, Supera-CBD targeted and quickly reduced inflammatory pain within 60 minutes, providing pain relief for up to five hours. Comparatively, traditional CBD had no effect on this type of pain in the same study. According to study researchers at a major academic center where the study was conducted, the results indicate that Supera-CBD may have an effect on the body’s TRPV1 pain system channels, which control heat-related pain.